• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Axsome Therapeutics, Inc.

    < Previous 1 2 Next >
    Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics to Participate in Investor Conferences in September
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics to Participate in Upcoming Investor Conferences
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics to Present at Upcoming Investor Conferences
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Recognizes May as Mental Health Awareness Month
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AXSM
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.